Investigational drug · Phase 3
BV100
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Hospital Acquired Bacterial Pneumonia (HABP), Ventilator Associated Bacterial Pneumonia (VABP), Colistin Resistanrt ABC.
Phase 3Last checked: Nov 19, 2026Latest source record: May 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
11
Any phase or sponsor naming "BV100"
First trial start
2026
Mar 27, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BV100", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hospital Acquired Bacterial Pneumonia (HABP)
- Ventilator Associated Bacterial Pneumonia (VABP)
- Colistin Resistanrt ABC
- Acinetobacter Baumannii-calcoaceticus Complex
- Blood Stream Infection
- Meningitis, Bacterial
- Ventriculitis, Infectious
Approved drugs for the same conditions: Pneumonia · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "BV100" as an intervention, largest first.
BioVersys SASIndustry
NCT07326540 · 248 participants (planned) · Start Mar 27, 2026 · Primary completion Dec 30, 2027
Drug: BV100 (300 mg); Polymyxin B and 3 more · For: Hospital Acquired Bacterial Pneumonia (HABP); Ventilator Associated Bacterial Pneumonia (VABP); Colistin Resistanrt ABC and 1 more
Sites: Tbilisi, Georgia
- Safety, Pharmacokinetics and Efficacy of BV100 Plus Low Dose Polymyxin B Plus Ceftazidime/Avibactam, or Plus Cefiderocol in Patients With Pulmonary and Extrapulmonary Infections Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus ComplexPivotal-lookingNot yet recruiting
BioVersys AGIndustry
NCT07431307 · 120 participants (planned) · Start Jul 2026 · Primary completion Mar 2028
Drug: BV100 with 50 mg polymyxin B plus ceftazidime/avibactam; BV100 with 50 mg polymyxin B plus cefiderocol and 1 more · For: Ventilator Associated Bacterial Pneumonia (VABP); Hospital Acquired Bacterial Pneumonia (HABP); Blood Stream Infection and 2 more
BioVersys SASIndustry
NCT04636983 · 54 participants · Start Nov 9, 2020 · Primary completion Dec 12, 2021
Drug: BV100; Placebo · For: Healthy Subjects
Sites: Neu-Ulm, Germany
BioVersys AGIndustry
NCT05086107 · 48 participants · Start Oct 8, 2021 · Primary completion May 30, 2022
Drug: BV100 · For: Renal Impairment
Sites: Miskolc, Hungary
BioVersys AGIndustry
NCT05685615 · 39 participants · Start Apr 20, 2023 · Primary completion Nov 1, 2024
Drug: BV100 plus Polymyxin B; BAT · For: Ventilator Associated Pneumonia
Sites: Tbilisi, Georgia; Athens, Greece; Heraklion, Greece · 16 sites in all
BioVersys AGIndustry
NCT05684705 · 35 participants · Start Sep 1, 2023 · Primary completion Oct 30, 2024
Drug: BV100 · For: Bacterial Infections
Sites: Vienna, Austria
BioVersys AGIndustry
NCT05537142 · 33 participants · Start Sep 2, 2022 · Primary completion Jul 30, 2024
Drug: BV100 · For: Healthy Participants
Sites: Kistarcsa, Hungary
BioVersys SASIndustry
NCT05087069 · 16 participants · Start Oct 8, 2021 · Primary completion Apr 8, 2022
Drug: BV100; Placebo · For: Healthy Volunteers
Sites: Neu-Ulm, Germany
- A Study to Assess Effect of BV100 on the Pharmacokinetics of Midazolam in Healthy ParticipantsCompleted
BioVersys AGIndustry
NCT05537090 · 16 participants · Start Sep 1, 2022 · Primary completion Jul 31, 2023
Drug: BV100; Midazolam · For: Healthy Volunteers
Sites: Kistarcsa, Hungary
BioVersys SASIndustry
NCT07580586 · 16 participants (planned) · Start Mar 22, 2026 · Primary completion Sep 30, 2026
Drug: BV100 (300 mg); Polymyxin B (50 mg) · For: Healthy Adult Participants
Sites: Vienna, Austria
Newest research
PubMed records naming it or its code names, newest first.
- Pulmonary penetration of intravenous rifabutin in healthy participants: A multiple-dose pharmacokinetic study.
Al Jalali V, Jorda A, Pracher L, et al. · Int J Antimicrob Agents 2026
- BV100 (rifabutin IV) drug interaction studies in healthy subjects with index CYP450 3A probes midazolam and itraconazole.
Delique P, Kemmer C, Husband L, et al. · J Antimicrob Chemother 2026
- Newly Emerging Nanotechnologies of Innovative Devices for Radioisotope Batteries.
Huang Q, Qin S, Huang R, et al. · Nanomaterials (Basel) 2026
- Single-ascending and multiple-ascending dose study of the pharmacokinetics, safety, and tolerability of BV100 (rifabutin for infusion) in healthy volunteers.
Kemmer C, Hirsch M, Reh C, et al. · Antimicrob Agents Chemother 2026
- Antibiotics and non-traditional antimicrobial agents for carbapenem-resistant Acinetobacter baumannii in Phase 1, 2, and 3 clinical trials.
Kontogiannis DS, Romanos LT, Tzvetanova ID, et al. · Expert Opin Investig Drugs 2025
- Carbapenem Resistance in Acinetobacter baumannii: Mechanisms, Therapeutics, and Innovations.
de Souza J, D'Espindula HRS, Ribeiro IF, et al. · Microorganisms 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.